Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia

BACKGROUND: The recently developed severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mRNA vaccine has a short history of use and further information is needed regarding its efficacy, especially in immunocompromised conditions, such as plasma cell dyscrasia (PCD). METHODS: We retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Tomotaka, Kusumoto, Shigeru, Kamezaki, Yoshiko, Hashimoto, Hiroya, Nishitarumizu, Nozomi, Nakanishi, Yoko, Kato, Yukiyasu, Kawai, Akimi, Matsunaga, Naohiro, Ebina, Toru, Nakamura, Tomoyuki, Marumo, Yoshiaki, Oiwa, Kana, Kinoshita, Shiori, Narita, Tomoko, Ito, Asahi, Inagaki, Atsushi, Ri, Masaki, Komatsu, Hirokazu, Aritsu, Takashi, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315730/
https://www.ncbi.nlm.nih.gov/pubmed/37102222
http://dx.doi.org/10.1002/cam4.5996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315730/
https://www.ncbi.nlm.nih.gov/pubmed/37102222
http://dx.doi.org/10.1002/cam4.5996

Ejemplares similares